Volume : 13, Issue : 10, October – 2026

Title:

FORMULATION AND IN VITRO EVALUATION OF METHOTREXATE -LOADED SOLID LIPID NANOPARTICLES

Authors :

Kethavath Deepthi, Sayeeda Naseer ,Shaik Sami, Netula Shiva Chandu,Kuruva Shiva Kumar,Nenavath ShivaLeela

Abstract :

The present study was aimed at the formulation and in vitro evaluation of Methotrexate-loaded Solid Lipid Nanoparticles (SLNs) to enhance drug delivery, improve stability, and achieve controlled release. Methotrexate, a poorly water-soluble anticancer drug, exhibits limited bioavailability, which can be improved through nanocarrier-based systems. SLNs were prepared using glyceryl monostearate as the lipid matrix and Tween 40/Span 80 as surfactants by a suitable lipid-based formulation technique. Four formulations (F1–F4) were developed and evaluated for physicochemical properties, particle size, zeta potential, entrapment efficiency, in vitro drug release, and stability studies. FTIR studies indicated no significant drug–excipient interactions, confirming compatibility. The optimized formulation (F4) exhibited the smallest particle size (119 nm), highest entrapment efficiency (85.6%), and highest zeta potential (-25.8 mV), indicating improved stability and effective drug encapsulation. In vitro release studies demonstrated sustained drug release up to 8 hours, with F4 showing maximum release (97.53%). Stability studies confirmed that the optimized formulation remained stable under different storage conditions over three months with minimal variation in drug content. The study concluded that SLNs are a promising drug delivery system for Methotrexate, significantly improving its release profile, stability, and encapsulation efficiency. Formulation F4 was identified as the optimized batch based on overall performance.
Keywords: Methotrexate, Solid Lipid Nanoparticles, Drug Delivery System, Sustained Drug Release, Entrapment Efficiency.

Cite This Article:

Please cite this article in press Kethavath Deepthi et al., Formulation And In Vitro Evaluation Of Methotrexate -Loaded Solid Lipid Nanoparticles.,. Indo Am. J. P. Sci, 2026; 13(10).

REFERENCES:

1. World Health Organization (WHO). Cancer Fact Sheet, 2023.
2. Bray F, et al. Global cancer statistics 2020: GLOBOCAN estimates. CA Cancer J Clin. 2021;71(3):209–249.
3. Kalyanaraman B. Teaching the basics of cancer metabolism. Free Radic Biol Med. 2017.
4. Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nat Rev Cancer. 2005.
5. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2020.
6. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196.
7. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery. Eur J Pharm Biopharm. 2000;50:161–177.
8. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach. Indian J Pharm Sci. 2009;71(4):349–358.
9. Souto EB, Müller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetics. Int J Pharm. 2010.
10. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in drug delivery. Int J Pharm. 2009.
11. Ekambaram P, Sathali AA, Priyanka K. Solid lipid nanoparticles: a review. Sci Revs Chem Commun. 2012;2(1):80–102.
12. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257–1272.
13. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations. J Control Release. 2011;146:1–10.
14. Ganesan P, Narayanasamy D. Lipid nanoparticles for drug delivery. Int J Pharm Investig. 2017;7(3):111–120.
15. Beloqui A, et al. Nanostructured lipid carriers for oral delivery. Nanomedicine. 2016;12:143–161.
16. Parveen R, Baboota S, Ali J, Ahuja A, Vasudev SS, Ahmad S. Preparation and evaluation of SLNs. AAPS PharmSciTech. 2009.